# Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

> **NCT02103335** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 38 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** pomalidomide
- **DRUG:** marizomib
- **DRUG:** low-dose dexamethasone

## Key facts

- **NCT ID:** NCT02103335
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-05
- **Primary completion:** 2016-10-03
- **Final completion:** 2016-11-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103335, "Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02103335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*